keyword
MENU ▼
Read by QxMD icon Read
search

primary hypercholesterolemia

keyword
https://www.readbyqxmd.com/read/29326775/a-systematic-review-on-the-prevalence-of-acute-myocardial-infarction-in-iran
#1
REVIEW
Jaber Mohseni, Toba Kazemi, Mahmood Hosseinzadeh Maleki, Hossein Beydokhti
In Iran, cardiovascular diseases are the most common causes of death. We aimed to perform a systematic review on the prevalence of acute myocardial infarction (AMI) in Iran based on Persian and English papers had been published from 1985 to 2015. Among 267 initially found articles, 142 were excluded; finally, a total number of 40 articles were found relevant which were reduced to 18. Smoking, hypertension, diabetes mellitus, and hypercholesterolemia were the most common risk factors for AMI. Premature MI prevalence was high in men, and smoking was the most common risk factor among young people...
October 2017: Heart Views: the Official Journal of the Gulf Heart Association
https://www.readbyqxmd.com/read/29295820/diet1-bile-acid-diarrhea-and-fgf15-19-mouse-model-and-human-genetic-variants
#2
Jessica M Lee, Jessica R Ong, Laurent Vergnes, Thomas Q de Aguiar Vallim, Jonathan Nolan, Rita M Cantor, Julian R F Walters, Karen Reue
Diet1 modulates intestinal production of the hormone fibroblast growth factor 15 (FGF15), which signals in liver to regulate bile acid synthesis. C57BL/6ByJ mice with a spontaneous Diet1 null mutation are resistant to hypercholesterolemia compared to wild-type C57BL/6J mice through enhanced cholesterol conversion to bile acids. To further characterize the role of Diet1 in metabolism, we generated Diet1-/- mice on the C57BL6/J genetic background. C57BL/6J Diet1-/- mice had elevated bile acid levels, reduced Fgf15 expression, and increased gastrointestinal motility and intestinal luminal water content, which are symptoms of bile acid diarrhea (BAD) in humans...
January 2, 2018: Journal of Lipid Research
https://www.readbyqxmd.com/read/29284999/high-burden-of-stroke-risk-factors-in-developing-country-the-case-study-of-bosnia-herzegovina
#3
Marija Bender, Edin Jusufovic, Vesna Railic, Sima Kelava, Selma Tinjak, Damir Dzevdetbegovic, Dario Mot, Mensuda Tresnjo, Sandra Lakicevic, Natasa Pejanovic-Skobic, Osman Sinanovic
Introduction: The burden of stroke has been increasing worldwide, especially in developing countries. Very few data regarding epidemiology of stroke are available in Bosnia and Herzegovina (BH). Patients and methods: We undertook a retrospective hospital-based study in all hospitals existing in five cantons and one district of BH. The patients were recruited between January 1st, 2014, and December 31st, 2014, and only first-ever-in-lifetime strokes (FES) were included for evaluation...
December 2017: Materia Socio-medica
https://www.readbyqxmd.com/read/29276932/-lisinopril-amlodipine-rosuvastatin-as-a-novel-fixed-combination-in-the-fight-against-cardiovascular-disease
#4
A E Semenova, I V Sergienko
The prevalence of multicomponent therapy in treatment of cardiovascular diseases makes fixed combinations of drugs very useful. The fixed combination of rosuvastatin with ACE inhibitor lisinopril and calcium antagonist amlodipine allows to control effectively two main cardiovascular risk factors: hypercholesterolemia and arterial hypertension. The efficacy of each of the components and their combined administration in primary and secondary prevention of cardiovascular disease has been demonstrated in clinical studies...
October 2017: Kardiologiia
https://www.readbyqxmd.com/read/29246151/suboptimal-control-of-lipid-levels-results-from-the-non-interventional-centralized-pan-russian-survey-of-the-undertreatment-of-hypercholesterolemia-ii-cepheus-ii
#5
Sergey Boytsov, Natalia Logunova, Yunona Khomitskaya
BACKGROUND: Elevated levels of low-density lipoprotein cholesterol (LDL-C) and glycosylated hemoglobin (HbA1c) are risk factors for cardiovascular complications. This study evaluated LDL-C goal attainment in Russian clinical practice among patients with moderate to very high cardiovascular risk. The study also assessed LDL-C goal attainment in patients prescribed lipid-lowering therapy for primary compared with secondary cardiovascular disease (CVD) prevention, predictors of LDL-C goal attainment, and the proportion of individuals with diabetes mellitus who achieved HbA1c < 7%...
December 16, 2017: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/29243274/target-achievement-with-maximal-statin-based-lipid-lowering-therapy-in-korean-patients-with-familial-hypercholesterolemia-a-study-supported-by-the-korean-society-of-lipid-and-atherosclerosis
#6
Jaewon Oh, Chan Joo Lee, Doo Il Kim, Moo-Yong Rhee, Byoung-Kwon Lee, Youngkeun Ahn, Byung Ryul Cho, Jeong-Taek Woo, Seung-Ho Hur, Jin-Ok Jeong, Yangsoo Jang, Sang-Hak Lee
BACKGROUND: Data on treatment results of lipid-lowering therapy (LLT) in familial hypercholesterolemia (FH) are limited, particularly in Asian patients. HYPOTHESIS: We sought to evaluate the target achievement rate and associated variables in Korean patients with FH after maximal statin-based LLT. METHODS: We enrolled 146 patients with heterozygous FH, and 90 patients were finally analyzed. Patients were initially prescribed rosuvastatin 10 mg or atorvastatin 20 mg, and the regimen was adjusted to achieve the low-density lipoprotein cholesterol (LDL-C) target of 100 mg/dL...
December 14, 2017: Clinical Cardiology
https://www.readbyqxmd.com/read/29228000/an-in-vivo-assessment-of-the-cholesterol-lowering-efficacy-of-lactobacillus-plantarum-ecgc-13110402-in-normal-to-mildly-hypercholesterolaemic-adults
#7
RANDOMIZED CONTROLLED TRIAL
Adele Costabile, Ivan Buttarazzi, Sofia Kolida, Sara Quercia, Jessica Baldini, Jonathan R Swann, Patrizia Brigidi, Glenn R Gibson
Coronary heart disease (CHD) is one of the major causes of death and disability in industrialised countries, with elevated blood cholesterol an established risk factor. Total plasma cholesterol reduction in populations suffering from primary hypercholesterolemia may lower CHD incidence. This study investigated the cholesterol reducing capacity of Lactobacillus plantarum ECGC 13110402, a strain selected for its high bile salt hydrolase activity, in 49 normal to mildly hypercholesterolaemic adults. Primary efficacy outcomes included effect on blood lipids (total cholesterol (TC), low density lipoproteins (LDL-C), high density lipoproteins (HDL-C) and triacylgycerides (TAG), inflammatory biomarkers and occurrence/severity of gastrointestinal side effects to establish safety and tolerance of the intervention...
2017: PloS One
https://www.readbyqxmd.com/read/29198514/erectile-dysfunction-medications-and-treatment-for-cardiometabolic-risk-factors-a-pharmacoepidemiologic-study
#8
Sean C Skeldon, Lucy Cheng, Steven G Morgan, Allan S Detsky, S Larry Goldenberg, Michael R Law
BACKGROUND: Erectile dysfunction (ED) can be a sentinel marker for future cardiovascular disease and has been described as providing a "window of curability" for men to receive targeted cardiovascular risk assessment. AIM: To determine whether the prescription of phosphodiesterase type 5 inhibitors (PDE5is) for ED leads to the detection and treatment of previously undiagnosed cardiometabolic risk factors. METHODS: We performed a retrospective population-based cohort study of residents of British Columbia, Canada using linked health care databases from 2004 to 2011...
December 2017: Journal of Sexual Medicine
https://www.readbyqxmd.com/read/29190549/cholesterol-oversynthesis-markers-define-familial-combined-hyperlipidemia-versus-other-genetic-hypercholesterolemias-independently-of-body-weight
#9
Lucía Baila-Rueda, Ana Cenarro, Itziar Lamiquiz-Moneo, Sofía Perez-Calahorra, Ana M Bea, Victoria Marco-Benedí, Estíbaliz Jarauta, Rocío Mateo-Gallego, Fernando Civeira
Primary hypercholesterolemia of genetic origin, negative for mutations in LDLR, APOB, PCSK9 and APOE genes (non-FH GH), and familial combined hyperlipidemia (FCHL) are polygenic genetic diseases that occur with hypercholesterolemia, and both share a very high cardiovascular risk. In order to better characterize the metabolic abnormalities associated with these primary hypercholesterolemias, we used noncholesterol sterols, as markers of cholesterol metabolism, to determine their potential differences. Hepatic cholesterol synthesis markers (desmosterol and lanosterol) and intestinal cholesterol absorption markers (sitosterol and campesterol) were determined in non-FH GH (n=200), FCHL (n=100) and genetically defined heterozygous familial hypercholesterolemia subjects (FH) (n=100) and in normolipidemic controls (n=100)...
November 27, 2017: Journal of Nutritional Biochemistry
https://www.readbyqxmd.com/read/29180351/proprotein-convertase-subtilisin-kexin-type-9-pcsk9-inhibitors-and-incident-type-2-diabetes-mellitus-a-systematic-review-and-meta-analysis-with-over-96-000-patient-years
#10
Luiz Sérgio F de Carvalho, Alessandra M Campos, Andrei C Sposito
OBJECTIVE: Like mutations with loss of function in the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene, inhibitors of PCSK9 (PCSK9i) may potentially favor the manifestation of diabetes. RESEARCH DESIGN AND METHODS: A meta-analysis of phase 2/3 randomized clinical trials (RCTs) assessed PCSK9i versus placebo in primary hypercholesterolemia setting. Statins and ezetimibe were used in 98.4% of these studies and balanced between PCSK9i and placebo. We calculated relative risks (RRs) and 95% CIs using random- and fixed-effect models...
November 27, 2017: Diabetes Care
https://www.readbyqxmd.com/read/29172973/ezetimibe-use-and-ldl-c-goal-achievement-a-retrospective-database-analysis-of-patients-with-clinical-atherosclerotic-cardiovascular-disease-or-probable-heterozygous-familial-hypercholesterolemia
#11
Joseph Menzin, Jyoti Aggarwal, Brian Boatman, Jeffrey Yu, Kevin Stern, David J Harrison, Jeetvan G Patel
BACKGROUND: Ezetimibe is recommended by clinical practice guidelines as a second-line therapy for lowering low-density lipoprotein cholesterol (LDL-C) levels, but little is known about its use and effectiveness in real-world populations. OBJECTIVE: To understand the real-world impact of adding or switching to ezetimibe on LDL-C goal achievement in patients with clinical atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH)...
December 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29171769/alirocumab-for-the-treatment-of-hyperlipidemia-in-high-risk-patients-an-updated-review
#12
Michael Farnier
Alirocumab is a fully human immunoglobulin G1 monoclonal antibody directed against proprotein convertase subtilisin/kexin type 9 (PCSK9) approved for the treatment of hypercholesterolemia in high-risk patients. The objective is to provide an updated review of the recent data published for alirocumab. Areas covered: The efficacy and safety of alirocumab has been initially evaluated in a comprehensive phase 3 program conducted in more than 6 000 patients with primary non-familial and heterozygous familial hypercholesterolemia: alirocumab reduced LDL-cholesterol up to 62% in phase 3 with every 2-week dosing compared with placebo, and up to 36% compared with ezetimibe, with an excellent safety and tolerability profile...
November 24, 2017: Expert Review of Cardiovascular Therapy
https://www.readbyqxmd.com/read/29153823/a-randomized-trial-evaluating-the-efficacy-and-safety-of-alirocumab-in-south-korea-and-taiwan-odyssey-kt
#13
Kwang Kon Koh, Chang Wook Nam, Ting-Hsing Chao, Ming-En Liu, Chiung-Jen Wu, Dong-Soo Kim, Chong-Jin Kim, Ivy Li, Jianyong Li, Marie T Baccara-Dinet, Pi-Jung Hsiao, Chern-En Chiang
BACKGROUND: Alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9, has been shown to provide significant reductions in low-density lipoprotein cholesterol (LDL-C). Data about its efficacy and safety in patients from South Korea and Taiwan are limited. OBJECTIVE: ODYSSEY KT assessed the efficacy and safety of alirocumab in patients from South Korea and Taiwan. METHODS: Patients with hypercholesterolemia at high cardiovascular risk who were on maximally tolerated statin were randomized (1:1) to alirocumab (75 mg every 2 weeks, with dose increase to 150 mg every 2 weeks at week 12 if LDL-C ≥70 mg/dL at week 8) or placebo for 24 weeks...
October 19, 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/29151496/cost-effectiveness-analysis-of-cardiovascular-disease-treatment-in-japan
#14
Satoshi Kodera, Arihiro Kiyosue, Jiro Ando, Hiroshi Akazawa, Hiroyuki Morita, Masafumi Watanabe, Issei Komuro
The quality-adjusted life year (QALY) and incremental cost-effectiveness ratio (ICER) are important concepts in cost-effectiveness analysis, which is becoming increasingly important in Japan. QALY is used to estimate quality of life (QOL) and life years, and can be used to compare the efficacies of cancer and cardiovascular treatments. ICER is defined as the difference in cost between treatments divided by the difference in their effects, with a smaller ICER indicating better cost-effectiveness. Here, we present a review of cost-effectiveness analyses in Japan as well other countries...
November 17, 2017: International Heart Journal
https://www.readbyqxmd.com/read/29150250/a-randomized-multicenter-double-blind-placebo-controlled-study-to-evaluate-the-efficacy-and-the-tolerability-of-a-triple-combination-of-amlodipine-losartan-rosuvastatin-in-patients-with-comorbid-essential-hypertension-and-hyperlipidemia
#15
Hae-Young Lee, Seok-Yeon Kim, Kee-Joon Choi, Byung-Su Yoo, Dong-Hun Cha, Hae Ok Jung, Dong-Ryeol Ryu, Joon Hyouk Choi, Kwang Je Lee, Tae Ho Park, Ju Hyeon Oh, Sang Min Kim, Ji-Yong Choi, Kye Hun Kim, Jaemin Shim, Woo-Shik Kim, Si-Wan Choi, Dae-Gyun Park, Pil-Sang Song, Taek-Jong Hong, Moo-Yong Rhee, Seung-Woon Rha, Seung Woo Park
PURPOSE: The objective of this study was to evaluate the efficacy and tolerability of a triple combination of amlodipine/losartan/rosuvastatin in patients with hypertension and hypercholesterolemia. METHODS: A randomized, multicenter, double-blind, placebo-controlled study was conducted. Eligible patients with hypertension and a sitting diastolic blood pressure (SiDBP) of >90 mm Hg and LDL-C levels <250mg/dL were screened. After a 4-week run-in period with therapeutic lifestyle changes and losartan potassium 100mg once daily, patients who met both blood pressure criteria (80 mm Hg ≤ SiDBP < 110 mm Hg) and the LDL-C level criteria (defined in the National Cholesterol Education Program Adult Treatment Panel III cardiovascular risk categories) were randomized to 1 of 3 groups and treated once daily for 8 weeks: losartan potassium 100mg + rosuvastatin 20mg treatment (L/R 100/20) group, amlodipine camsylate 5mg + losartan potassium 100mg treatment (A/L 5/100) group, and amlodipine 5mg+ losartan potassium 100mg + rosuvastatin 20mg (A/L/R 5/100/20) group...
November 14, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/29121968/association-of-ifitm3-rs12252-polymorphisms-bmi-diabetes-and-hypercholesterolemia-with-mild-flu-in-an-iranian-population
#16
Parvaneh Mehrbod, Sana Eybpoosh, Fatemeh Fotouhi, Hadiseh Shokouhi Targhi, Vahideh Mazaheri, Behrokh Farahmand
BACKGROUND: IFITM3 has been suggested to be associated with infection in some ethnic groups. Diabetes and hypercholesterolemia are also important clinical conditions that can predispose individuals to infection. The aim of this study was to investigate the association of rs12252 C polymorphism, BMI, diabetes, and hypercholesterolemia with mild flu in an Iranian population. METHODS: We conducted a case-control study, including 79 mild flu and 125 flu-negative individuals attending primary care centers of three provinces of Iran (i...
November 9, 2017: Virology Journal
https://www.readbyqxmd.com/read/29110223/the-effectiveness-and-cost-effectiveness-of-plant-sterol-or-stanol-enriched-functional-foods-as-a-primary-prevention-strategy-for-people-with-cardiovascular-disease-risk-in-england-a-modeling-study
#17
Wei Yang, Heather Gage, Daniel Jackson, Monique Raats
This study appraises the effectiveness and cost-effectiveness of consumption of plant sterol-enriched margarine-type spreads for the prevention of cardiovascular disease (CVD) in people with hypercholesterolemia in England, compared to a normal diet. A nested Markov model was employed using the perspective of the British National Health Service (NHS). Effectiveness outcomes were the 10-year CVD risk of individuals with mild (4-6 mmol/l) and high (above 6 mmol/l) cholesterol by gender and age groups (45-54, 55-64, 65-74, 75-85 years); CVD events avoided and QALY gains over 20 years...
November 6, 2017: European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care
https://www.readbyqxmd.com/read/29082583/the-risk-of-ischaemic-stroke-in-primary-antiphospholipid-syndrome-patients-a-prospective-study
#18
M Radin, K Schreiber, I Cecchi, D Roccatello, M J Cuadrado, S Sciascia
BACKGROUND AND PURPOSE: The most common neurological manifestation of antiphospholipid syndrome (APS) is ischaemic stroke. Identifying patients with APS at high risk for developing any thrombotic event remains a major challenge. In this study, the aim was to identify predictive factors of ischaemic stroke in a cohort of primary APS (PAPS) patients who presented with new onset symptoms suggestive of acute stroke. METHODS: This prospective multicentre study included 36 consecutive PAPS patients who presented with new onset symptoms suggestive of an acute stroke...
October 30, 2017: European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies
https://www.readbyqxmd.com/read/29078037/the-effects-of-single-and-multiple-dose-administration-of-bococizumab-rn316-pf-04950615-a-humanized-igg2%C3%AE-a-monoclonal-antibody-binding-proprotein-convertase-subtilisin-kexin-type-9-in-hypercholesterolemic-subjects-treated-with-and-without-atorvastatin-results
#19
Barry Gumbiner, Tenshang Joh, Hong Liang, Hong Wan, Matteo Levisetti, Alicia M Vana, David L Shelton, Philippe Forgues, Stephan Billotte, Jaume Pons, Charles M Baum, Pamela D Garzone
AIMS: Three single-dose and one multiple-dose phase I studies were conducted in subjects with primary hypercholesterolemia to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of bococizumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. METHODS: The dosing schedules for hypercholesterolemic subjects randomized in the four phase I studies were: 1) ascending, single, intravenous (IV) bococizumab (0.3, 1, 3, 6, 12, or 18 mg/kg) or placebo (N=48; baseline low-density lipoprotein cholesterol [LDL-C] ≥130 mg/dL); 2) single, IV bococizumab (0...
October 27, 2017: Cardiovascular Therapeutics
https://www.readbyqxmd.com/read/29075885/long-term-metabolic-effects-of-aripiprazole-ziprasidone-and-quetiapine-a-pragmatic-clinical-trial-in-drug-na%C3%A3-ve-patients-with-a-first-episode-of-non-affective-psychosis
#20
Javier Vázquez-Bourgon, Rocío Pérez-Iglesias, Víctor Ortiz-García de la Foz, Paula Suárez Pinilla, Álvaro Díaz Martínez, Benedicto Crespo-Facorro
INTRODUCTION: The use of second-generation antipsychotics (SGA) has been associated with metabolic changes. However, there are differences in the metabolic profile between SGAs. We have previously observed that ziprasidone had a more benign early metabolic profile compared to aripiprazole and quetiapine. However, a long-term follow-up is preferred to detect clinically relevant impairment in metabolic parameters. We aimed to compare the effect of aripiprazole, ziprasidone, and quetiapine on metabolic measures in first-episode non-affective psychosis patients after 1 year of treatment...
January 2018: Psychopharmacology
keyword
keyword
65021
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"